Articles From: Gilbane Building Company to Expand Use of Textura-CPM Internationally at Gilbane Federal Unit to Glacier Announces Quarterly Dividend


Gilbane Building Company to Expand Use of Textura-CPM Internationally at Gilbane Federal Unit Leading General Contractor Broadens Global Use of Payment Management Solution Following Successes on Projects in Europe and Mexico Canada NewsWire CHICAGO , Jan.
Sign-up for Gilbane Building Company to Expand Use of Textura-CPM Internationally at Gilbane Federal Unit investment picks
Leading General Contractor Broadens Global Use of Payment Management Solution Following Successes on Projects in Europe and Mexico CHICAGO , Jan.
Sign-up for Gilbane Building Company to Expand Use of Textura-CPM Internationally at Gilbane Federal Unit investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0982983001&sourceType=1 http://www.ccnmatthews.com/logos/20110803-gildan_200_2.jpg MONTREAL, QUEBEC --
Sign-up for Gildan Activewear Announces Plan to Buy Back Shares Through Private Agreements investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0985008001&sourceType=1 http://www.ccnmatthews.com/logos/20110803-gildan_200_2.jpg MONTREAL, QUEBEC --
Sign-up for Gildan Activewear Appoints James Kehoe as Executive Vice-President, Chief Financial and Administrative Officer investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0988630001&sourceType=1 http://www.ccnmatthews.com/logos/20110803-gildan_200_2.jpg MONTREAL, QUEBEC --
Sign-up for Gildan Activewear Will Hold its Conference Call for the Quarter Ending January 4, 2015 at 5:00 PM ET on February 4, 2015 and Hold its Annual Meeting of Shareholders at 10:00 AM ET... investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0980158001&sourceType=1 http://www.ccnmatthews.com/logos/20110803-gildan_200_2.jpg MONTREAL, QUEBEC --
Sign-up for Gildan Activewear Will Hold its Fiscal 2014 Fourth Quarter and Full Year Results Conference Call at 8:30 AM ET on December 4, 2014 investment picks
Gilead Sciences, Inc. (Nasdaq:GILD) today announced an expansion to its agreement with Janssen R&D Ireland for the development and commercialization of a new once-daily single tablet regimen containing Gilead’s tenofovir alafenamide (TAF) and emtricitabine, and Janssen’s rilpivirine.
Sign-up for Gilead Announces Amended Agreements With Janssen to Develop and Commercialize Tenofovir Alafenamide-Based Single Tablet Regimens for HIV Treatment investment picks
Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from several Phase 2 and Phase 3 studies evaluating investigational uses of Harvoni ® (ledipasvir 90 mg/sofosbuvir 400 mg) for the treatment of chronic hepatitis C virus (HCV) infection in patients with limited or no treatment options, including patients with decompensated cirrhosis, patients with HCV recurrence following a liver transplant and patients who failed previous treatment with other direct acting antivirals.
Sign-up for Gilead Announces Harvoni Study Results in Chronic Hepatitis C Patients with Advanced Liver Disease and Those Who Failed Prior Treatment investment picks
Gilead Sciences, Inc. (Nasdaq:GILD) today announced data from three Phase 2 open-label studies evaluating the safety and efficacy of an investigational all-oral pan-genotypic regimen containing the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved as Sovaldi ® by the U.S. Food and Drug Administration in December 2013, and the investigational NS5A inhibitor GS-5816 for the treatment of chronic hepatitis C virus (HCV) infection.
Sign-up for Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C investment picks
Gilead Sciences, Inc. (NASDAQ: GILD) today announced long-term follow-up results from the registration studies further describing the duration of response, progression-free survival (PFS) and safety profile for Zydelig ® (idelalisib) in relapsed patients with chronic lymphocytic leukemia (CLL) and two types of indolent non-Hodgkin lymphoma (iNHL). The findings are being presented this week at the Annual Meeting of the American Society of Hematology (ASH). Zydelig is indicated in the United States as monotherapy for patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies, and in combination with rituximab for patients with relapsed CLL for whom rituximab alone would be considered appropriate therapy due to comorbidities.
Sign-up for Gilead Presents Follow-up Data from Zydelig Registrational Studies in Patients with Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma investment picks
Gilead Sciences, Inc. (NASDAQ: GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $4 billion, in an underwritten, registered public offering, consisting of three tranches: The senior notes are rated A- by Standard & Poor's and A3 by Moody's.
Sign-up for Gilead Prices $4 Billion of Senior Unsecured Notes investment picks
Gilead Sciences, Inc. (Nasdaq:GILD) and Phenex Pharmaceuticals AG, a privately-held biotechnology company, today announced the signing of a definitive agreement under which Gilead will acquire Phenex’s Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH). Under the terms of the agreement, Gilead will pay Phenex an upfront payment plus additional payments based upon achievement of certain development milestones that may potentially be worth up to $470 million.
Sign-up for Gilead Sciences Announces Acquisition of Phenex Pharmaceuticals’ Development Program for Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases investment picks
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the quarter ended September 30, 2014.
Sign-up for Gilead Sciences Announces Third Quarter 2014 Financial Results investment picks
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the 33 rd Annual J.P. Morgan Healthcare Conference in San Francisco.
Sign-up for Gilead Sciences to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13 investment picks
Gilead Sciences' stock (GILD) slumped 3.5% in after-hours trade Tuesday, after the biotechnology company reported third-quarter profit that missed expectations.
Sign-up for Gilead Sciences' stock pulls back from record high close after earnings miss investment picks
Drugmaker Gilead Sciences Inc. (GILD) recorded its largest single-session fall since its January 1992 initial public offering Monday after a pharmacy benefit manager dropped the company's Hepatitis C drug in favor of a rival's product.
Sign-up for Gilead sees largest one-day drop since IPO investment picks
Gilead Sciences Inc. shares (GILD) climbed about 3% in early trade Monday and were among the top S&P 500 gainers, after Morgan Stanley upgraded the stock to overweight from equal-weight.
Sign-up for Gilead shares up 3% as Morgan Stanley upgrades to overweight investment picks
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide (TAF) 10 mg (E/C/F/TAF) for the treatment of HIV-1 infection in adults.
Sign-up for Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV investment picks
Gilead Sciences Inc. (GILD) said Tuesday it is buying Phenex Pharmaceuticals AG's Farnesoid X Receptor (FXR) program, which comprises small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH). As part of the deal, Gilead will pay the privately-held German company an upfront payment plus additional payments based on certain milestones that could be worth up to $470 million.
Sign-up for Gilead to buy liver disease treatment from Germany's Phenex investment picks
By Russ Britt, MarketWatch Retail giant to focus on biotech firm's $1,000-a-day pills LOS ANGELES (MarketWatch) -- Shares of Gilead Sciences Inc. were up more than 2% Monday after the biotechnology giant scored an exclusive rights deal with the nation's largest drug-store chain, CVS Health Corp., for two Hepatitis C treatments that cost $1,000 per pill or more.
Sign-up for Gilead, CVS strike deal on Hepatitis C drugs investment picks
SAN DIEGO, Calif., Dec.
Sign-up for Gilman Louie Joins Cubic Executive Advisory Board investment picks
2014/11/11
American Automobile Association, Max Muscle, Wingstop and Sport Clips coming soon! OAK BROOK, Ill.
Sign-up for Gilroy Continues Revitalization as Pacheco Pass Signs over 9,000 Square Feet in New Leases investment picks
2014/11/25
Why wait in long lines this holiday season when you can give the PECO Smart Gift of Energy instead?
Sign-up for Give the Gift of Warmth this Holiday Season with the PECO Smart Gift of Energy investment picks
2014/11/17
Find out where you can recycle in your area MILWAUKEE , Nov.
Sign-up for Give your car battery another life investment picks
2014/11/24
- Review of offers within RetailMeNot's database of deals from 2013 shows Thanksgiving and Black Friday promotions both had an average discount of 37% off - It's not just Black Friday that draws the early birds; 80% of respondents said they would wake up early Thanksgiving Day to shop for a deal - Over 1 in 5 (21%) Black Friday shoppers report that they have never missed a year of shopping for deals on Black Friday AUSTIN, Texas , Nov.
Sign-up for Giving Thanks for Good Deals: Despite Backlash, Thanksgiving Day Becomes a Preferred Shopping Holiday, With Black Friday Holding Strong investment picks
2014/12/16
Chicago O’Hare International Airport is the busiest airport in the U.S., with more than five million Americans coming through the airport in December for the past several years.
Sign-up for Giving the Gift of Tech Advice: Geek Squad Arrives at Chicago O’Hare International Airport This Holiday with First-Ever ‘Pro Bono’ Precinct investment picks
ADVISORY, Oct.
Sign-up for GLAAD to Ring The Nasdaq Stock Market Opening Bell investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0985535001&sourceType=1 http://www.ccnmatthews.com/logos/20081113-gvc.gif VANCOUVER, BRITISH COLUMBIA --
Sign-up for Glacier Announces Asset Sale investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0979041001&sourceType=1 http://www.ccnmatthews.com/logos/20081113-gvc.gif VANCOUVER, BRITISH COLUMBIA --
Sign-up for Glacier Announces Quarterly Dividend investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Gilbane Building Company to Expand Use of Textura-CPM Internationally at Gilbane Federal Unit to Glacier Announces Quarterly Dividend
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent